Minerva Neurosciences, Inc.

Dedicated to transforming the lives of people affected by central nervous system diseases through innovative science that addresses patients' unmet needs.

About Us

Dedicated to transforming lives

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe contain innovative mechanisms of action. As we work to advance our current product pipeline, we plan to explore additional indications identify new product candidates from our existing intellectual property, and acquire rights to additional promising product candidates with significant therapeutic potential. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs.

Our strategy is based on the following key principles: innovative clinical development with a focus on mechanisms behind the disease, patient safety and compliance; scientific rigor; continually leveraging patient and caregiver insights to drive scientific advancement; and an unparalleled commitment to integrity in all of our business dealings. As we work to advance our pipeline of products through clinical development and regulatory review, we may also selectively explore collaborations with leading pharmaceutical companies.


Executive Management Team

Remy Luthringer, PhD

Remy Luthringer, PhD

President and Chief Executive Officer

Dr. Remy Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.

Geoff Race, FCMA, MBA

Geoff Race, FCMA, MBA

Executive Vice President and
Chief Financial Officer

Prior to being named as Minerva Neurosciences' CFO, Mr. Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012. He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.

Joseph Reilly

Joseph Reilly

Senior Vice President and Chief Operating Officer

Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation. In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.

Fred Ahlholm

Fred Ahlholm

Senior Vice President and Chief Accounting Officer

Fred Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. Fred is a CPA and earned his BBA at the University of Notre Dame.

Mark Levine

Mark Levine

Senior Vice President, General Counsel and Secretary

Mark Levine has extensive experience counseling companies on general corporate matters, complex commercial transactions, mergers and acquisitions, securities law, corporate governance and regulatory compliance. Prior to joining Minerva Neurosciences in 2014, he served in senior legal positions at athenahealth, Inc., Clinical Data, Inc., Wheelabrator Technologies Inc., and Xpedior Incorporated. He holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.

Board of Directors

Marc Beer

Marc D. Beer has served on our Board and as Chairman since December 2013. Mr. Beer served as Chief Executive Officer and a member of the board of directors of Aegerion Pharmaceuticals. Inc., a publicly traded pharmaceutical company, from August 2010 to July 2015. From November 2007 to August 2010, Mr. Beer served as an independent consultant and member of the board of directors for a number of private life sciences companies. From April 2000 to November 2007, he served as the President and Chief Executive Officer of ViaCell, Inc., a cellular therapy company. Prior to that, from April 1996 to 2000, he held marketing and business development roles at Genzyme Corporation, a Sanofi pharmaceutical company, most recently serving as Vice President of Global Marketing. Mr. Beer has also served as a member of the board of directors for Erytech Pharma, a publicly traded biopharmaceutical company and the Emerging Companies section of the Biotechnology Industry Organization (BIO), a trade organization. Mr. Beer is also Chairman of the board of directors of Good Start Genetics, Inc. (a privately held molecular diagnostics company), a strategic consultant to OvaScience and a member of the Notre Dame Research and Commercialization Advisory Committee, Notre Dame Graduate Studies Research and Advisory Council and Miami University Business Advisory Council. Mr. Beer holds a B.S. from Miami University (Ohio).

Remy Luthringer, PhD

Dr. Remy Luthringer is the President and Chief Executive Officer of Minerva Neurosciences, Inc. He has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.

Jan van Heek

Jan van Heek has served on our Board since July 2014. Since 2009, Mr. van Heek has been a Principal and Partner at BioPoint Group, a business development consulting company, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint in 2009, Mr. van Heek spent more than 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, most recently as an Executive Vice President and Senior Advisor to the chief executive officer and senior management team. Mr. van Heek is currently a board member of Amarin Corporation, a publicly traded biopharmaceutical company. He was also a board member and Chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford Business School.

Francesco De Rubertis, PhD

Francesco de Rubertis, PhD, has served as a member of our Board since our inception in August 2007. Dr. de Rubertis has been a Founder Partner of Index Ventures (UK) LLP, a venture capital firm since July 2009, which provides investment advice to the Index Funds. He was also a co-founder of that firm’s life sciences practice. Prior to that, from 1998 to July 2009, he served as a Senior Partner in Index Ventures, SA, in the same capacity. Dr. de Rubertis has also served and continues to serve on the boards of directors of various public and private life sciences companies, including Molecular Partners AG, Versartis Inc. and Egalet Corporation. Dr. de Rubertis received his Laurea from the University of Pavia (Italy) and a Ph.D. from the University of Geneva (Switzerland).

David Kupfer, MD

Dr. Kupfer joined our Board in November 2015. He is an international leader in psychiatry who has authored more than 1,100 articles, books and book chapters. Dr. Kupfer chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. He is Distinguished Professor emeritus of Psychiatry at the University of Pittsburgh School of Medicine. As director of research at Western Psychiatric Institute and Clinic (WPIC), Dr. Kupfer helped establish WPIC as one of the nation’s preeminent university-based psychiatric research centers. He is founding president of the International Society of Bipolar Disorders and was elected to the National Academy of Medicine in 1990.

Fouzia Laghrissi-Thode, MD

Dr. Laghrissi-Thode has nearly 20 years of experience in the pharmaceutical industry, and has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently vice president of the cardiovascular and metabolism therapy area at AstraZeneca. Her business development and licensing accomplishments include demonstrated successes in global product strategy, franchise development and expansion, collaborations, corporate partnerships and joint ventures. Dr. Laghrissi-Thode holds an M.D. from the University of Tours School of Medicine in France, is board certified in psychiatry and is adjunct professor of psychiatry at the University of Pittsburgh.

Michele Ollier, MD

Michèle Ollier, MD, has served as a member of our Board since our inception in August 2007. Dr. Ollier is a Life Science partner at Index Ventures, a venture capital firm, whose investments are focused in information technology and life science companies, including the Index Funds, which she joined in February 2006. From January 2003 to January 2006, Dr. Ollier was Director of Investment in Life Sciences at Edmond de Rothschild Investment Partners in Paris. Prior to that, Dr. Ollier held various positions relating to strategy, development and commercialization of pharmaceutical products at several biotechnology and pharmaceutical companies, including International CNS Product Manager at Sanofi, Lipid Lowering Agents Group Director at Bristol Myers Squibb France, International Oncology Director at Rhone Poulenc Rorer/RPR Gencell and International Vice President Reproductive Health at Serono. Dr. Ollier has also served as a member of the board of directors for Aegerion Pharmaceuticals Inc., a publicly traded pharmaceutical company and various private life sciences companies. Dr. Ollier holds a medical degree from Paris-Ouest University (France).

Nico Vandervelpen

Nico Vandervelpen has been a member of our Board since August 2014. Mr. Vandervelpen previously served in a variety of capacities at Limburgse Reconversie Maatschappij NV, or LRM, a Belgium-based private equity and venture capital firm, including most recently as Chief Operating Officer and Managing Director of BioVille (a bioincubator). Prior to joining LRM, between 1998 and 2007, Mr. Vandervelpen was a senior executive at Ernst & Young. Mr. Vandervelpen serves on the board of directors of several public and private life sciences companies. He has led several dozen venture capital transactions and M&A deals. Mr. Vandervelpen holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.


Targeting a range of unmet needs in CNS

Minerva Neurosciences is focused on the central nervous system (CNS) disease pharmaceutical market. Our pipeline targets the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease, each of which affects millions of people around the world. Currently available treatment options for these conditions are known to have significant limitations that can often result in high rates of discontinuation of therapy and unsatisfactory efficacy and safety profiles. Family members also often face significant challenges associated with the burden of these and many other CNS diseases. We are pursuing the development of new therapeutic options based on our deep knowledge of the pathology of CNS diseases, the pharmacology of our compounds and our understanding of desired outcomes for unmet patient needs. We believe our product candidates have novel mechanisms of action and represent differentiated treatment options with the potential to address significant unmet needs with improved efficacy and safety.

Minerva's Pipeline

We currently have a portfolio of first-in-class product candidates in the pipeline: MIN-101, MIN-117, MIN-202 and MIN-301.

Pipeline of Next Generation Central Nervous System Pharmaceuticals (Status as of November, 2015)

Program Primary
Phase I Phase II Rights
MIN-101 Schizophrenia
  • 6 trials completed
  • Once a day formulation completed
  • Phase IIa completed
  • Phase IIb enrollment ongoing, with topline data expected Q2 2016
Global ex-Asia
MIN-117 Major depressive disorder (MDD)
  • 2 trials completed
  • Enrollment ongoing in Phase IIa trial, with topline data expected H1 2016
Global ex-Asia
MIN-202 Insomnia
  • Phase Ib in MDD patients completed
  • Bioavailability study in healthy volunteers completed
  • Multiple ascending dose study in healthy volunteers completed
  • Enrollment ongoing in Ib trial in comorbid insomnia, with topline data expected H1 2016
  • Enrollment ongoing in Phase IIa trial in insomnia, with topline data expected H1 2016
European Union
MIN-301 Parkinson's disease
  • Pre-clinical studies ongoing in preparation for IMPD or IND filing with a Phase I expected to initiate thereafter


Patients suffering with schizophrenia present with (1) positive symptoms, such as delusions, hallucinations, thought disorders, and agitation, (2) negative symptoms, such as mood flatness and lack of pleasure in daily life, (3) cognitive symptoms, such as the decreased ability to understand information and make decisions, difficulty focusing, and decreased working memory function, and (4) sleep disorders. Our lead product candidate, MIN-101, is an innovative molecule behaving as an antagonist on 5-HT2A and sigma-2 receptors. It is in development for the treatment of patients affected by schizophrenia and, in particular, those suffering from negative symptoms of the disease.

Most currently approved therapies for schizophrenia show efficacy primarily in the management of positive symptoms. As a result, patients with predominantly negative symptoms are often underserved. Side effects of current pharmaceutical treatment options include sedation, uncontrollable muscle movements, weight gain, cognitive impairment, and sleep disorders. Due to its particular pharmacologic profile, MIN-101 has the potential to address negative and cognitive symptoms and improve sleep while addressing overall symptoms of schizophrenia for patients in treatment as well as for treatment-naive patients, all with an improved side effect profile compared to the current standard of care. In a Phase IIA, placebo-controlled trial, clinically significant improvement of negative symptoms and a trend toward the improvement of positive and cognitive symptoms and overall psychopathology was observed after three months of drug administration. We hold the exclusive license for this molecule from Mitsubishi Tanabe Pharma Corporation.


M117 is an innovative molecule behaving as an antagonist on 5-HT1A and 5-HTT receptors and both serotonin and dopamine reuptake. It is in development for the treatment of MDD, a mood disorder in which feelings of sadness, loss, anger or frustration interfere with a person's ability to carry out and enjoy once-pleasurable activities. Current therapies are linked with several side effects, including, among others, sleep problems, headache, anxiety or restlessness, cognitive impairments, weight gain and sexual dysfunction. Further, due to their mechanisms of action, some current treatment options take up to four weeks to have a noticeable effect, which can expose patients to a period of vulnerability and suicide risk.

Two Phase I clinical trials have confirmed the safety and tolerability profile of MIN-117 and the potential for once-a-day administration. Further, the effects on sleep of MIN-117 in the Phase I clinical trials indicate a potential onset of action in MDD patients within just a few days. We hold the exclusive license for this molecule from Mitsubishi Tanabe Pharma Corporation.


MIN-202 is an innovative molecule acting as a selective orexin-2 receptor antagonist for the treatment of primary and secondary insomnia. The major drawbacks of current insomnia medications are that immediate-onset therapies taken at bedtime can interfere with natural sleep onset and deep sleep patterns. As a result, patients can experience residual effects the following day, such as daytime sedation, slowed or distorted reaction-time, and cognitive impairment. We believe MIN-202 is an advanced compound that targets the action of wakefulness-promoting neurons, which we believe is likely to result in better safety and tolerability and preservation of physiologic and restorative sleep. We are jointly developing MIN-202 under a co-development and license agreement with Janssen Pharmaceutica N.V., a Johnson & Johnson company.


MIN-301 is a recombinant form of the neuregulin-1β1 peptide and is currently in preclinical development for the treatment of Parkinson's disease. Current treatments for Parkinson's disease have been shown to improve symptoms for many patients, but they have not been proven to delay the onset of disease, slow or prevent disease progression, or reverse its effects. Research involving multiple preclinical models mimicking Parkinson's disease symptoms has been carried out with MIN-301. The results obtained thus far show that the peptide has the potential to restore motor function distorted in Parkinson's patients, with a positive effect on cognition. We own the rights globally to the MIN-301 peptide.

Investors and Media

The Minerva Neurosciences team is focused on its commitment to deliver long-term value to investors through solid business planning and execution.
Visit Site


Minerva Neurosciences, Inc.

1601 Trapelo Road, Suite 284
Waltham, MA 02451
For general inquiries, please contact:

For investor and media inquiries, please contact:
William Boni
Vice President, Investor Relations and Corporate Communications

© Copyright 2014-2015 Minerva Neurosciences Inc., All Rights Reserved
Privacy Policy | Terms of Use